Changes in Hong Kong stocks | Pegasus Medical-B (09996) rose by more than 5%, the highest revenue increase in the first half of the year, 23%, and more than 660 cases were implanted in mainland China

The Zhitong Finance App learned that Peijia Medical-B (09996) rose by more than 5%. As of press release, it had risen 4.75% to HK$5.29, with a turnover of HK$2,866,800.

According to the news, Peijia Healthcare recently revealed that revenue for the first half of this year was approximately RMB 415 million to RMB 435 million, an increase of about 17.4% to 23.1% over the previous year. Mainly due to the continuous expansion of the transcatheter valve treatment business, driven by the successful commercialization of products for new indications; the neurological intervention business continues to grow driven by the penetration of self-developed products and strategic cooperation.

During the reporting period, the total number of TAVR implants was about 2,830, a significant increase of about 36.5% over the same period of the previous year in terms of implantation volume, and hospital coverage was expanded to more than 850 in Greater China; TaurTiO®, specially designed for aortic valve reflux (AR), was commercialized, and more than 660 cases were implanted in mainland China, showing good clinical acceptance and commercialization potential.